Wealth Enhancement Advisory Services
MDGL icon

Wealth Enhancement Advisory Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Buy
+615
New +$315K ﹤0.01% 3103
2026
Q1 		– Sell
-1,513
Closed -$844K – 3769
2025
Q4 		$844K Buy
1,513
+805
+114% +$411K ﹤0.01% 2069
2025
Q3 		$309K Buy
708
+7
+1% +$2.61K ﹤0.01% 2769
2025
Q2 		$210K Buy
+701
New +$209K ﹤0.01% 2955
2025
Q1 		– Sell
-680
Closed -$210K – 3080
2024
Q4 		$210K Buy
+680
New +$191K ﹤0.01% 2662
2024
Q2 		– Sell
-973
Closed -$260K – 2666
2024
Q1 		$260K Buy
+973
New +$229K ﹤0.01% 2009

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wealth Enhancement Advisory Services's MDGL Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 615 shares worth $330K. The stake represents ﹤0.01% of the portfolio and ranks #3103 among its holdings. This is a return to the name: Wealth Enhancement Advisory Services previously reported a position in MDGL as recently as Q4 2025.

Wealth Enhancement Advisory Services first reported a position in MDGL in Q1 2024 and has held it in 6 quarters since. The position peaked at $844K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Wealth Enhancement Advisory Services held 615 shares of Madrigal Pharmaceuticals worth $330K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3103 holding.
  • Wealth Enhancement Advisory Services first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Madrigal Pharmaceuticals position peaked at $844K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.